These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32845528)

  • 21. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
    Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
    J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X; Niu QT; Warmington KS; Asuncion FJ; Dwyer D; Grisanti M; Han CY; Stolina M; Eschenberg MJ; Kostenuik PJ; Simonet WS; Ominsky MS; Ke HZ
    Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lentiviral delivery of PPARγ shRNA alters the balance of osteogenesis and adipogenesis, improving bone microarchitecture.
    James AW; Shen J; Khadarian K; Pang S; Chung G; Goyal R; Asatrian G; Velasco O; Kim J; Zhang X; Ting K; Soo C
    Tissue Eng Part A; 2014 Oct; 20(19-20):2699-710. PubMed ID: 24785569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diet-Stimulated Marrow Adiposity Fails to Worsen Early, Age-Related Bone Loss.
    McGrath C; Little-Letsinger SE; Pagnotti GM; Sen B; Xie Z; Uzer G; Uzer GB; Zong X; Styner MA; Rubin J; Styner M
    Obes Facts; 2024; 17(2):145-157. PubMed ID: 38224679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sclerostin antibody treatment rescues the osteopenic bone phenotype of TGFβ inducible early gene-1 knockout female mice.
    Gingery A; Subramaniam M; Pitel KS; Li X; Ke HZ; Turner RT; Iwaniec UT; Hawse JR
    J Cell Physiol; 2020 Jul; 235(7-8):5679-5688. PubMed ID: 31975377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
    Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
    J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.
    Chandra A; Lin T; Young T; Tong W; Ma X; Tseng WJ; Kramer I; Kneissel M; Levine MA; Zhang Y; Cengel K; Liu XS; Qin L
    J Bone Miner Res; 2017 Feb; 32(2):360-372. PubMed ID: 27635523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
    Ominsky MS; Niu QT; Li C; Li X; Ke HZ
    J Bone Miner Res; 2014 Jun; 29(6):1424-30. PubMed ID: 24967455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.
    Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD
    Bone; 2022 Jan; 154():116201. PubMed ID: 34537437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
    Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
    Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
    Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
    Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of Gsα in osteocytes leads to osteopenia due to sclerostin induced suppression of osteoblast activity.
    Fulzele K; Dedic C; Lai F; Bouxsein M; Lotinun S; Baron R; Divieti Pajevic P
    Bone; 2018 Dec; 117():138-148. PubMed ID: 30266511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
    Zhang D; Hu M; Chu T; Lin L; Wang J; Li X; Ke HZ; Qin YX
    Bone; 2016 Jun; 87():161-8. PubMed ID: 26868528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sclerostin antibody promotes bone formation through the Wnt/β-catenin signaling pathway in femoral trochlear after patellar instability.
    Xu C; Ji G; Chen X; Yan L; Liang T; Liu J; Wang F
    Connect Tissue Res; 2023 Mar; 64(2):148-160. PubMed ID: 36379907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody.
    Boyce RW; Brown D; Felx M; Mellal N; Locher K; Pyrah I; Ominsky MS; Taylor S
    Bone Rep; 2018 Jun; 8():90-94. PubMed ID: 29955626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
    Allison H; Holdsworth G; McNamara LM
    BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats.
    Qin W; Li X; Peng Y; Harlow LM; Ren Y; Wu Y; Li J; Qin Y; Sun J; Zheng S; Brown T; Feng JQ; Ke HZ; Bauman WA; Cardozo CC
    J Bone Miner Res; 2015 Nov; 30(11):1994-2004. PubMed ID: 25974843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.